IMC Chicago’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $84.2M | Buy |
387,100
+34,000
| +10% | +$7.54M | 0.03% | 346 |
|
|
2025
Q4 | $80.7M | Sell |
353,100
-143,000
| -29% | -$32.6M | 0.03% | 348 |
|
|
2025
Q3 | $115M | Buy |
496,100
+223,000
| +82% | +$45.4M | 0.04% | 248 |
|
|
2025
Q2 | $50.7M | Sell |
273,100
-119,400
| -30% | -$22.2M | 0.02% | 376 |
|
|
2025
Q1 | $82.2M | Sell |
392,500
-86,600
| -18% | -$16.8M | 0.05% | 208 |
|
|
2024
Q4 | $85.1M | Buy |
479,100
+51,100
| +12% | +$9.4M | 0.04% | 232 |
|
|
2024
Q3 | $84.5M | Buy |
428,000
+121,100
| +39% | +$22.6M | 0.05% | 205 |
|
|
2024
Q2 | $52.6M | Buy |
306,900
+53,000
| +21% | +$8.78M | 0.03% | 285 |
|
|
2024
Q1 | $46.2M | Buy |
253,900
+11,400
| +5% | +$1.96M | 0.03% | 267 |
|
|
2023
Q4 | $37.6M | Buy |
242,500
+1,500
| +0.6% | +$219K | 0.03% | 316 |
|
|
2023
Q3 | $35.9M | Buy |
241,000
+24,100
| +11% | +$3.54M | 0.03% | 255 |
|
|
2023
Q2 | $29.2M | Buy |
216,900
+25,400
| +13% | +$3.72M | 0.03% | 289 |
|
|
2023
Q1 | $30.5M | Sell |
191,500
-1,500
| -0.8% | -$229K | 0.04% | 250 |
|
|
2022
Q4 | $31.2M | Sell |
193,000
-38,000
| -16% | -$5.83M | 0.05% | 227 |
|
|
2022
Q3 | $31M | Sell |
231,000
-48,100
| -17% | -$6.9M | 0.04% | 208 |
|
|
2022
Q2 | $42.7M | Buy |
279,100
+66,300
| +31% | +$10.1M | 0.06% | 155 |
|
|
2022
Q1 | $34.5M | Sell |
212,800
-89,000
| -29% | -$12.9M | 0.03% | 236 |
|
|
2021
Q4 | $40.9M | Buy |
301,800
+39,900
| +15% | +$4.71M | 0.03% | 238 |
|
|
2021
Q3 | $28.3M | Buy |
261,900
+79,800
| +44% | +$9.12M | 0.03% | 286 |
|
|
2021
Q2 | $20.5M | Buy |
182,100
+51,100
| +39% | +$5.76M | 0.03% | 322 |
|
|
2021
Q1 | $14.2M | Sell |
131,000
-45,600
| -26% | -$4.88M | 0.02% | 371 |
|
|
2020
Q4 | $18.9M | Buy |
176,600
+58,500
| +50% | +$5.62M | 0.02% | 288 |
|
|
2020
Q3 | $10.3M | Buy |
118,100
+6,800
| +6% | +$640K | 0.02% | 307 |
|
|
2020
Q2 | $10.9M | Sell |
111,300
-69,700
| -39% | -$6.14M | 0.02% | 253 |
|
|
2020
Q1 | $13.8M | Sell |
181,000
-105,500
| -37% | -$8.99M | 0.03% | 171 |
|
|
2019
Q4 | $25.4M | Buy |
286,500
+125,900
| +78% | +$10.5M | 0.07% | 99 |
|
|
2019
Q3 | $12.2M | Buy |
160,600
+5,100
| +3% | +$350K | 0.04% | 157 |
|
|
2019
Q2 | $11.3M | Buy |
155,500
+46,000
| +42% | +$3.62M | 0.04% | 158 |
|
|
2019
Q1 | $8.82M | Buy |
109,500
+49,800
| +83% | +$4.07M | 0.03% | 159 |
|
|
2018
Q4 | $5.5M | Buy |
+59,700
| New | +$5.25M | 0.02% | 186 |
|
Other funds holding ABBV
VCM
VPM
IMC Chicago's ABBV Position: Q1 2026 in Review
IMC Chicago sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 91,287 shares — an estimated $20.2M sold.
IMC Chicago first reported a position in ABBV in Q4 2019 and held it in 10 quarters. The position peaked at $20.9M in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- IMC Chicago reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
- IMC Chicago sold 91,287 AbbVie shares in Q1 2026, an estimated $20.2M.
- IMC Chicago first reported a position in AbbVie in Q4 2019 and held it in 10 quarters.
- IMC Chicago's AbbVie position peaked at $20.9M in Q4 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.